^
BIOMARKER:

CDKN2A deletion

i
Other names: CDKN2A, ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf, Cyclin-dependent kinase inhibitor 2A
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
CDKN2A deletion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive
:
C3
CDKN2A deletion
Mantle Cell Lymphoma
ibrutinib
Resistant
:
C3
CDKN2A deletion
Acute Lymphocytic Leukemia
blinatumomab
Sensitive
:
C3
CDKN2A deletion
Melanoma
Immunotherapy
Resistant
:
C3
CDKN2A deletion
Gallbladder Cancer
palbociclib
Resistant
:
C3
CDKN2A deletion
Glioma
vincristine + lomustine + procarbazine hydrochloride
Resistant
:
C3
CDKN2A deletion
Hepatocellular Cancer
Immunotherapy
Sensitive
:
C3
CDKN2A deletion
Melanoma
palbociclib
Sensitive
:
C3
CDKN2A deletion
Pancreatic Cancer
palbociclib
Resistant
:
C3
CDKN2A deletion
Gastric Adenocarcinoma
Immunotherapy
Resistant
:
C3
CDKN2A deletion
Diffuse Large B Cell Lymphoma
T-lymphocyte cell therapy
Resistant
:
C3
CDKN2A deletion
Prolymphocytic Leukemia
alemtuzumab
Resistant
:
C4
CDKN2A deletion
Estrogen Receptor Positive Breast Cancer
palbociclib + VRx-510
Sensitive
:
D
CDKN2A deletion
Estrogen Receptor Positive Breast Cancer
ribociclib + VRx-510
Sensitive
:
D
CDKN2A deletion
Ewing Sarcoma
ASP7487
Sensitive
:
D
CDKN2A deletion
Ewing Sarcoma
palbociclib
Sensitive
:
D
CDKN2A deletion
Renal Cell Carcinoma
temsirolimus
Sensitive
:
D
CDKN2A deletion
Pancreatic Ductal Adenocarcinoma
BET inhibitor + CDK inhibitor
Sensitive
:
D
CDKN2A deletion
HER2 Positive Breast Cancer
abemaciclib + tucatinib
Sensitive
:
D
CDKN2A deletion
Pancreatic Ductal Adenocarcinoma
palbociclib + JQ-1
Sensitive
:
D